<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methyldopa</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00968</strong>&#160; (APRD01106)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00968/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00968/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00968.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00968.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00968.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00968.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00968.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00968">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(S)-(-)-alpha-Methyldopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>3-Hydroxy-alpha-methyl-L-tyrosine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Alpha medopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>alpha-Methyl dopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Alphamethyldopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>AMD</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>L-alpha-Methyldopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>L-Methyl Dopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>&#945;-methyl-L-dopa</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Methyldopa sesquihydrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000988/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000988/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000988">DBSALT000988</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aldomet</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aldometil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aldomin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dopamet</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hypolag</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Medomet</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Medopren</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Novomedopa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nu-Medopa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Aldoclor</td><td>Chlorothiazide + Methyldopa</td></tr><tr><td>Aldoril</td><td>Hydrochlorothiazide + Methyldopa</td></tr><tr><td>Apo Methazide</td><td>Hydrochlorothiazide + Methyldopa</td></tr><tr><td>Novo-Doparil</td><td>Hydrochlorothiazide + Methyldopa</td></tr><tr><td>PMS-Dopazide</td><td>Hydrochlorothiazide + Methyldopa</td></tr><tr><td>Supres</td><td>Chlorothiazide + Methyldopa</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/sympatholytics">Sympatholytics</a></li>
<li><a href="/mesh/adrenergic-alpha-2-receptor-agonists">Adrenergic alpha-2 Receptor Agonists</a></li></ul></td></tr><tr><th>CAS number</th><td>555-30-6</td></tr><tr><th>Weight</th><td>Average: 211.2145<br>Monoisotopic: 211.084457909</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>13</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>CJCSPKMFHVPWAR-UEQNJFAPNA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/s2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenols and Derivatives</td></tr><tr><th>Direct parent</th><td>Catecholamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Phenylpropanoic Acids; Alpha Amino Acids and Derivatives; Amphetamines and Derivatives; Amino Fatty Acids; Polyols; Enolates; Carboxylic Acids; Polyamines; Enols; Monoalkylamines</td></tr><tr><th>Substituents</th><td>polyol; carboxylic acid; enolate; enol; polyamine; carboxylic acid derivative; amine; primary amine; primary aliphatic amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in the treatment of hypertension.</td></tr><tr><th>Pharmacodynamics</th><td>Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the <i>L</i>-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.</td></tr><tr><th>Mechanism of action</th><td>Although the mechanism of action has yet to be conclusively demonstrated, the resultant hypotensive effect is most likely due to the drug's action on the CNS. Methyldopa is converted into the metabolite, alpha-methylnorepinephrine, in the CNS, where it stimulates the central inhibitory alpha-adrenergic receptors, leading to a reduction in sympathetic tone, total peripheral resistance, and blood pressure. Reduction in plasma renin activity, as well as the inhibition of both central and peripheral norepinephrine and serotonine production may also contribute to the drug's antihypertensive effect, although this is not a major mechanism of action. This is done through the inhibition of the decarboxylation of dihydroxyphenylalanine (dopa)&#8212;the precursor of norepinephrine&#8212;and of 5-hydroxytryptophan (5-HTP)&#8212;the precursor of serotonin&#8212;in the CNS and in most peripheral tissues.</td></tr><tr><th>Absorption</th><td>Absorption from the gastrointestinal tract is variable but averages approximately 50%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Low (less than 20%).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, extensively metabolized. The known urinary metabolites are: a-methyldopa mono-0-sulfate; 3-0-methyl-a-methyldopa; 3,4-dihydroxyphenylacetone; a-methyldopamine; 3-0-methyl-a-methyldopamine and their conjugates.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Methyldopa</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00703">3-O-methyl-a-methyldopa</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/724">Details</a></td></tr><tr><td>Methyldopa</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00704">3-O-methyl-a-methyldopamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/725">Details</a></td></tr><tr><td>Methyldopa</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00784">a-methyldopa mono-0-sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/805">Details</a></td></tr><tr><td>Methyldopa</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00785">a-methyldopamine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/806">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Methyldopa is extensively metabolized. The known urinary metabolites are: &#945;-methyldopa mono-O-sulfate; 3-0-methyl-&#945;-methyldopa; 3,4-dihydroxyphenylacetone; &#945;-methyldopamine; 3-0-methyl-&#945;-methyldopamine and their conjugates. Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-O-sulfate conjugate. Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.</td></tr><tr><th>Half life</th><td>The plasma half-life of methyldopa is 105 minutes.</td></tr><tr><th>Clearance</th><td><ul>
	<li>Renal cl=130 mL/min [healthy]</li>
</ul></td></tr><tr><th>Toxicity</th><td>The oral LD<sub>50</sub> of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9374</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9276</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6066</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9852</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9895</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9357</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7757</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6053</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9369</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9491</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9233</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.864</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9551</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8185
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8997
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8077
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.6281 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9939
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9629
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Merck and co inc</li>
<li>Merck research laboratories div merck co inc</li>
<li>Accord health care inc</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Halsey drug co inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Parke davis div warner lambert co</li>
<li>Pliva inc</li>
<li>Purepac pharmaceutical co</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Superpharm corp</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Hospira inc</li>
<li>Luitpold pharmaceuticals inc</li>
<li>Marsam pharmaceuticals llc</li>
<li>Smith and nephew solopak div smith and nephew</li>
<li>Teva parenteral medicines inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.chcsct.com">Central Texas Community Health Centers</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.emcure.co.in">Emcure Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.endo.com">Endo Pharmaceuticals Inc.</a></li>
<li><a href="http://www.hhlabs.com">H and H Laboratories</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.luitpold.com">Luitpold Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Aldoclor 250-250 mg tablet</td><td>0.67USD</td><td>tablet</td></tr><tr><td>Methyldopa 500 mg tablet</td><td>0.67USD</td><td>tablet</td></tr><tr><td>Methyldopa 250 mg tablet</td><td>0.39USD</td><td>tablet</td></tr><tr><td>Apo-Methyldopa 500 mg Tablet</td><td>0.27USD</td><td>tablet</td></tr><tr><td>Methyldopate 250 mg/5 ml vial</td><td>0.24USD</td><td>ml</td></tr><tr><td>Apo-Methyldopa 250 mg Tablet</td><td>0.15USD</td><td>tablet</td></tr><tr><td>Apo-Methyldopa 125 mg Tablet</td><td>0.1USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>300 dec &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>1E+004 mg/L (at 25 &#176;C)</td><td>MERCK INDEX (1996)</td></tr><tr><td>logP</td><td>-1.7</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.26e+00 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>-2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>-1.4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>1.73</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.85</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>103.78</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>53.79</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>20.73</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p><a href="http://www.drugsyn.org/Methyldopa.htm">DrugSyn.org</a></p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=2868818&amp;tbm=pts" target="_blank">US2868818 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Mah GT, Tejani AM, Musini VM: Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003893. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19821316">Pubmed</a></li>
	<li>McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. 2009 Feb 15;66(4):337-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19202042">Pubmed</a></li>
	<li>Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17485976">Pubmed</a></li>
	<li>van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1363322">Pubmed</a></li>
	<li>Rosenthal T, Oparil S: The effect of antihypertensive drugs on the fetus. J Hum Hypertens. 2002 May;16(5):293-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12082488">Pubmed</a></li>
	<li>van Zwieten PA, Timmermans PB: Pharmacology and characterization of central alpha-adrenoceptors involved in the effect of centrally acting antihypertensive drugs. Chest. 1983 Feb;83(2 Suppl):340-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6295709">Pubmed</a></li>
	<li>van Zwieten PA: Pharmacology of centrally acting hypotensive drugs. Br J Clin Pharmacol. 1980;10 Suppl 1:13S-20S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/6104975">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D08205" target="_blank">D08205 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07194" target="_blank">C07194 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=61058" target="_blank">61058 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL459" target="_blank">CHEMBL459 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000226" target="_blank">DAP000226 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450453" target="_blank">PA450453 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=426830" target="_blank">426830 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/methyl.htm" target="_blank">http://www.rxlist.com/cgi/generic2/methyl.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/methyldopa.html" target="_blank">http://www.drugs.com/cdi/methyldopa.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ald1012.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ald1012.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Methyldopa" target="_blank">Methyldopa <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C02AB01<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C02#C02">C02 &#8212; ANTIHYPERTENSIVES</a></li><li><a href="/atc/C02A#C02A">C02A &#8212; ANTIADRENERGIC AGENTS, CENTRALLY ACTING</a></li><li><a href="/atc/C02AB#C02AB">C02AB &#8212; Methyldopa</a></li></ul>C02AB02<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C02#C02">C02 &#8212; ANTIHYPERTENSIVES</a></li><li><a href="/atc/C02A#C02A">C02A &#8212; ANTIADRENERGIC AGENTS, CENTRALLY ACTING</a></li><li><a href="/atc/C02AB#C02AB">C02AB &#8212; Methyldopa</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:08.16</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00968.pdf?1265922796">show</a>(155 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00968.pdf?1265922736">show</a>(53.4 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00521">Carteolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00841">Dobutamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00988">Dopamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00494">Entacapone</a></td><td>Entacapone may increase the effect and toxicity of the sympathomimetic, methyldopa.</td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01364">Ephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Methyldopa increases haloperidol effect or risk of psychosis</td></tr><tr><td><a href="/drugs/DB01592">Iron</a></td><td>Iron decreases the absorption of dopa derivatives</td></tr><tr><td><a href="/drugs/DB00893">Iron Dextran</a></td><td>Iron decreases the absorption of dopa derivatives</td></tr><tr><td><a href="/drugs/DB01064">Isoprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01235">L-DOPA</a></td><td>Methyldopa increases the effect and toxicity of levodopa</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01365">Mephentermine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00610">Metaraminol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00723">Methoxamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01203">Nadolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00368">Norepinephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01580">Oxprenolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01359">Penbutolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00388">Phenylephrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB01291">Pirbuterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01366">Procaterol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB01001">Salbutamol</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Increased arterial pressure</td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Methyldopa. Concomitant therapy is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid natural licorice.</li>
<li>Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.</li>
<li>May take Vitamin D.</li>
<li>No iron, zinc or fluoride within 2 hours of taking this medication.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>